✨A rising star from "Ankara University Medical Oncology Department", sevinç ballı , is presenting her study conducted under the mentorship of Yüksel Ürün about the predictive models in patients with bladder cancer! ✅ 📍Visit her in the poster area at 2006P Emre Yekedüz

In patients with mHSPC #prostatecancer randomized ph2 trial👉adding Lutetium-177 (Pluvicto) to docetaxel met primary end point👉significantly improved undetectable PSA at 48 weeks Outstanding talk by Arun Azad Congrats Arun, Michael Hofman ESMO - Eur. Oncology #ESMO24 OncoAlert UroToday.com

Original Article: Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (CheckMate 067) nej.md/4dUqm0g #ESMO24 | ESMO - Eur. Oncology

#SunRISe-4 trial explores #TAR-200 and cetrelimab combination for #BladderCancer treatment. Andrea Necchi and Zach Klaassen discuss study results showing promising efficacy for the combination therapy and the importance of multidisciplinary care > bit.ly/4de1r6y #ESMO24

Great job Dana Rathkopf ESMO - Eur. Oncology presenting on our new AR degrader! Now published in Annals of Oncology for more details: annalsofoncology.org/article/S0923-… DCI Center for Prostate & Urologic Cancers The PCCTC Duke Cancer MSK Oncology Updates

💫🌟👏👏👏 🎓🔝Toni Choueiri, MD OncoAlert 🌟💫

Exciting news for #ESMO25 in Berlin! Congratulations to Toni Choueiri, MD on being named the scientific co-chair. Looking forward to an incredible event and groundbreaking discussions in oncology. #cancer #Oncology ESMO - Eur. Oncology Deborah Mukherji OncoAlert FabriceAndre

Promising predictive biomarkers in mHSPC: Understanding these biomarkers can guide personalized treatment strategies. OncoAlert #cancer #oncology @nivenmehra

#ESMO24 recap is here! 📺 Important data, expert opinions – all available now on #high5oncologyTV. Free & on demand! high5oncology.tv/meeting-covera… #Oncology #ESMO2024 #MedicalUpdates Evandro de Azambuja, MD, PhD Eva M Ciruelos Javier Cortes MD PhD Carmen Criscitiello G Curigliano MD PhD Rebecca Dent AGO Breast Study Group

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA) out on The Lancet Oncology and presented at #ESMO24 thelancet.com/journals/lanon… The UpFrontPSMA phase 2 trial evaluated the use of Lutetium-177

NIAGARA shows that perioperative durvalumab plus neoadjuvant chemotherapy significantly improves event-free survival and overall survival in patients with muscle-invasive bladder cancer compared to neoadjuvant chemotherapy alone. NEJM Tom Powles #ESMO24 @oncoalert ESMO - Eur. Oncology

💫🌟🔬 Adjuvant Pembrolizumab in High-Risk Bladder Cancer Lead Author: Andrea Apolo, M.D.🌟💫 OncoAlert OncoReporte NIH #bladdercancer 🔹 Pembrolizumab almost doubles cancer-free survival after surgery compared to observation alone. 🔹 Median cancer-free time: 29.6 vs. 14.2 months.

💫🌟🔬 Pembrolizumab adyuvante en cáncer de vejiga de alto riesgo Andrea Apolo, M.D.🌟💫 OncoAlert OncoReporte NIH #CáncerDeVejiga 🔹 Pembrolizumab casi duplica la supervivencia libre de cáncer tras cirugía vs. observación. 🔹 Tiempo libre de cáncer: 29.6 vs. 14.2 meses. 🔹 Eficaz

💫🌟🔬💥 BCL2 Expression in Advanced Prostate Cancer Dr. Daniel Westaby, Dr. Johann de Bonno 🌟💫 OncoAlert Advanced Prostate Cancer Consensus Conference 🔹 BCL2 expression is enriched in AR-negative mCRPC, linked to shorter overall survival. 🔹 High BCL2 associates with lineage plasticity and resistance to

📣 We are happy to announce that 🎓#IUCS24 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 4.5 European CME credits (ECMEC®s)! Register now for free! 👉 ow.ly/u6oY50TpZUr #urology #cancer

💫🌟💥🔬 UpFrontPSMA Study: Combined Therapy in Metastatic Prostate Cancer by Arun Azad et al. 🌟💫 OncoAlert Advanced Prostate Cancer Consensus Conference 🔹 41% of patients achieved undetectable PSA at 48 weeks with [¹⁷⁷Lu]Lu-PSMA-617 + docetaxel. 🔹 Only 16% with docetaxel alone. 🔹 Significant

💫🌟💥🔬 Estudio UpFrontPSMA: Terapia combinada en cáncer de próstata metastásico por Arun Azad. OncoAlert OncoReporte Advanced Prostate Cancer Consensus Conference 🔹 41% de los pacientes con PSA indetectable a las 48 semanas con [¹⁷⁷Lu]Lu-PSMA-617 + docetaxel. 🔹 PSA indetectable en solo 16% con

💫🌟🚨 OncoAlert #ESMO24 Newsletter is here! 🚨 Don't miss our top picks of the best trials from the entire congress! #Oncology #CancerResearch #ClinicalTrials

💫🌟💡 New consensus recommendations from the International Bladder Cancer Group on bladder-sparing therapy for BCG-unresponsive NMIBC. #BladderCancer #Oncology #BladderPreservation

💫🌟📊 The HERO trial reaffirmed the inclusion of adult patients with prostate cancer, requiring at least 1 year of ADT, testosterone ≥150, and a PSA >2 if no prior local therapy. OncoAlert UroToday.com 🔹️The study spanned across diverse subgroups, showing relugolix superior to